Business Wire

Autolus Announces Appointment of Andrew J. Oakley as Senior Vice President and Chief Financial Officer

Jaa

Autolus Therapeutics Limited (to be reorganised as Autolus Therapeutics plc) (“Autolus”), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the appointment of Andrew J. Oakley as its Senior Vice President and Chief Financial Officer, effective prior to the closing of Autolus’ planned initial public offering.

Dr. Christian Itin, Autolus’ Chairman and Chief Executive Officer, commented:

“We are delighted to welcome Andrew to Autolus. Andrew brings a wealth of international finance experience to Autolus, having been a CFO for public life science companies for more than 15 years. His proven ability to successfully manage growth is an excellent fit for Autolus and our drive to unlock the potential of T cell therapies in oncology.”

Andrew Oakley said:

“I am excited to join Autolus as Senior Vice President and Chief Financial Officer at this transformational stage in the company’s development. Autolus aims to be a leading global programmed T cell therapy company and I look forward to working with my new colleagues as we progress our programmed T cell therapies through development and towards commercialisation.”

Andrew joins Autolus from Sosei Group Corporation where he served as its executive vice president and chief financial officer since February 2017. Prior to that, he served as chief financial officer, company secretary and executive board member of Vectura Group plc from January 2015 to June 2016, as chief financial officer of NovImmune SA from March 2014 to November 2014 and as executive vice president and chief financial officer of Actelion Pharmaceuticals Ltd from January 2003 to August 2013. He has also held a senior finance role at Accenture, executive leadership positions in major multinational building material companies, and has spent several years as an equity analyst with banks in Australia, the United Kingdom and the United States.

Andrew holds a Bachelor of Economics degree from Macquarie University and an MBA from London Business School and has been a Member of the Australian Institute of Chartered Accountants since 1987.

About Autolus
Autolus is a private, clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognise cancer cells, break down their defence mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of haematological malignancies and solid tumours.

For further information, please visit the company’s website at: www.autolus.com

Contact information

Investor Contact
S.A. Noonan Communications, LLC
Susan A. Noonan
212 966 3650
susan@sanoonan.com
or
Media Contact
JW Communications
Julia Wilson
+44 (0)7818 430877
juliawilsonuk@gmail.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

PMI Launches Search for Next President and CEO22.10.2018 17:00Tiedote

Project Management Institute (PMI), the world’s leading professional membership organization for project managers, announced today that it has retained Heidrick & Struggles to help the organization find its next President and Chief Executive Officer (CEO). The dynamic leader shall oversee the implementation of a new strategic plan and guide the organization toward a future designed to help thousands of project professionals around the world accelerate their careers and make ideas a reality. Heidrick & Struggles is a premier provider of executive search, leadership assessment and development, organization and team effectiveness, and culture shaping services globally. PMI will conduct a comprehensive global review of both internal and external candidates for this key position. The selected candidate will embody PMI’s core values and possess the skillsets necessary to advance the organization’s key goals. PMI’s next President and CEO will help it execute a bold new multi-year initiative d

E2open to Acquire INTTRA, Adding the World’s Leading Ocean Shipping Network and Software Provider, Creating an Integrated Global Supply Chain and Logistics Operating Network22.10.2018 16:43Tiedote

E2open, the one place in the cloud to run your supply chain, today announced the acquisition of INTTRA, the leading ocean shipping network, software and information provider. The combination of INTTRA’s ocean carrier and shipper network with E2open’s industry leading business network will create a unified global logistics and supply chain network. E2open and INTTRA will join efforts to strengthen the connections and streamline the information flow between manufacturers, suppliers, shipping service providers, ocean carriers and all the participants in global trade. E2open is the largest cloud-based provider of networked supply chain solutions, featuring a complete portfolio of applications that enable the world’s most complex supply chains to better plan, collaborate, and execute their end-to-end operations. More than 70,000 partner companies and 200,000 users, many of the biggest brands and manufacturers across a range of industries, use the E2open network and platform to orchestrate t

Patient-Data Platform Raremark Raises £3m to Enable Precision Medicine in Rare Disease22.10.2018 15:00Tiedote

Raremark, the leading patient-data platform in rare disease, has raised £3m in funding from investors, led by AlbionVC and Ananda Ventures, with participation from Oltre Venture and from existing major investor the Cass Entrepreneurship Fund. The funding will be used to develop Raremark’s patient-engagement and data-analysis technology, helping biopharmaceutical companies to identify, engage and learn from patients, accelerating the development of new treatments. Raremark’s platform is the foundation for building research networks of rare disease patients and their families. Raremark provides biopharmaceutical companies with access to anonymized and aggregated patient data, helping to reduce the time and cost of clinical development. The Raremark platform engages and retains patients, leveraging machine-learning technologies in novel ways. The approach is designed to raise health literacy and informed participation in medical research, to improve the quality of existing therapies and t

Celltrion Healthcare Hosts Forum with Patient Advocacy Groups to Provide Information on the Use of Biosimilars in Oncology22.10.2018 14:50Tiedote

To coincide with the ESMO 2018 Congress in Munich, Germany, Celltrion Healthcare invited perspective from experts including a physician and pharmacist to provide information to patient advocacy groups on the history of biosimilars, how they are tested and approved, their cost saving benefit and the wealth of clinical evidence already available on their use in order to improve understanding of biosimilars. The introduction of biosimilars in the treatment of cancer has the potential to reduce pressure on healthcare budgets and increase access to other innovative treatments or more potent regimens. This is achieved by offering more cost-effective alternatives to the reference medicinal products and by increasing competition in the market. Breast cancer is the most common cancer in women worldwide and accounts for a quarter of all cancer diagnoses in women.1 For the benefits of biosimilar use to be realised in oncology, and in the treatment of breast cancer, barriers to their uptake need t

Sony Corporation Selects ANAQUA for IP Management22.10.2018 14:00Tiedote

Anaqua, Inc., the leading provider of innovation and intellectual property (IP) management solutions, today announced that multinational technology company Sony Corporation has entered into a multi-year agreement to use the ANAQUA software to manage its patent and trademark portfolios. Sony is one of the world’s largest technology and entertainment companies, with products spanning consumer electronics, smart phones, game and network services, financial services, and professional products. “We are excited to welcome one of the world’s largest companies and IP leaders to Anaqua’s growing client community,” said Bob Romeo, CEO of Anaqua. “Sony’s decision to strategically partner with Anaqua for their IP Management system reinforces our continued investment in the APAC market.” ABOUT ANAQUA The most innovative companies in the world innovate with Anaqua. Its simplified software platform combines insight from big data analytics with critical tools, best practice workflows and advanced serv

Dentsu Aegis Network Announces the Acquisition of Namics AG22.10.2018 14:00Tiedote

Dentsu Aegis Network today announces that it has signed a definitive agreement to acquire Namics AG, a leading full-service digital agency in Switzerland and Germany. Following the acquisition, which is subject to approval from the German competition authority, the company will become ‘Namics - A Merkle Company’. Namics’ digital experience, creative and service design expertise complements Merkle’s already significant customer experience (CX) and marketing technology practice in the region. An important step in Merkle’s strategy to increase its global footprint, it provides further scale and depth to Merkle’s people-based marketing capabilities, in particular in the areas of business transformation strategy, digital consulting and technology implementation across Adobe Experience Cloud, Sitecore, Salesforce and SAP and other leading technology partners. All Namics‘ 550 digital specialists based in Frankfurt, Hamburg, Munich, St. Gallen, Zurich and Belgrade will join Merkle, bringing it

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme